ICON Public Limited (NASDAQ:ICLR) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of ICON Public Limited (NASDAQ:ICLR) have been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are currently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $279.17.

ICLR has been the topic of a number of recent research reports. Truist Financial lowered their target price on ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Robert W. Baird lowered their price objective on ICON Public from $221.00 to $203.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Leerink Partners reaffirmed an “outperform” rating and set a $255.00 target price (down from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. William Blair reiterated an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $263.00 price target on shares of ICON Public in a research report on Wednesday, January 15th.

Hedge Funds Weigh In On ICON Public

A number of hedge funds have recently made changes to their positions in ICLR. Natixis Advisors LLC raised its position in shares of ICON Public by 6.7% in the fourth quarter. Natixis Advisors LLC now owns 177,761 shares of the medical research company’s stock valued at $37,279,000 after buying an additional 11,177 shares during the last quarter. State of Tennessee Department of Treasury raised its holdings in ICON Public by 1.0% in the 4th quarter. State of Tennessee Department of Treasury now owns 158,947 shares of the medical research company’s stock valued at $33,333,000 after acquiring an additional 1,600 shares during the last quarter. Kornitzer Capital Management Inc. KS raised its holdings in ICON Public by 40.6% in the 4th quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company’s stock valued at $20,363,000 after acquiring an additional 28,050 shares during the last quarter. Motley Fool Wealth Management LLC boosted its holdings in shares of ICON Public by 2.3% during the 4th quarter. Motley Fool Wealth Management LLC now owns 64,038 shares of the medical research company’s stock worth $13,342,000 after purchasing an additional 1,466 shares during the last quarter. Finally, Foyston Gordon & Payne Inc grew its position in shares of ICON Public by 27.3% in the fourth quarter. Foyston Gordon & Payne Inc now owns 51,713 shares of the medical research company’s stock valued at $10,845,000 after purchasing an additional 11,089 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Stock Performance

ICLR opened at $185.77 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.34 and a debt-to-equity ratio of 0.36. ICON Public has a 12-month low of $174.93 and a 12-month high of $347.72. The firm has a 50 day moving average of $195.57 and a two-hundred day moving average of $229.43. The firm has a market capitalization of $15.00 billion, a PE ratio of 19.49, a P/E/G ratio of 1.86 and a beta of 1.21.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.01. The firm had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.04 billion. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. On average, analysts anticipate that ICON Public will post 13.38 EPS for the current year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.